Cannabis sativa: A look at protozoa, helminths, insect vectors, and pests

Guerra, Rhanoica Oliveira; Neto, José Rodrigues do Carmo; Silva, Priscilla Elias Ferreira da; Borges, Yarlla Loyane Lira; Franco, Pablo Igor Ribeiro; Machado, Juliana Reis; Silva, Marcos

doi:10.1016/j.fitote.2023.105467

Cited by 4 publications

(2 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chinese culture indicates it for rheumatic pain, intestinal constipation, menstrual disorders, and malaria; in the ancient Egypt it was used as an antiinflammatory agent for the eyes; and in India, as a part of the mixture to suppress anxiety [ 16 ]. Moreover, it has been utilized in the treatment of a wide variety of other diseases including epilepsy, seizure disorders, depression, insomnia, pain, asthma, nausea, and diarrhea [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…Cannabinoids have the ability to affect various types of infectious agents. When parasites were treated in vitro or in vivo with cannabinoids, it has been observed to inhibit the proliferation, growth, and invasion of these pathogens [ 17 ]. According to the etiologic agent causing the infectious and parasitic diseases, treatments administered together with cannabinoids can significantly interfere with the control of the parasitemia and the clinical outcome of the disease [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anthelmintic Effect of Cannabidiol against Echinococcus granulosus sensu stricto

Albani,

Fuentes,

Ramírez

et al. 2024

TropicalMed

View full text Add to dashboard Cite

Cystic echinococcosis is a global parasitic zoonosis caused by infection with the larval stage of Echinococcus granulosus sensu lato. Cystic echinococcosis affects more than 1 million people worldwide, causing important economic costs in terms of management and livestock associated losses. Albendazole is the main drug used in treating human cystic echinococcosis. In spite of this, its low aqueous solubility, poor absorption, and consequently erratic bioavailability are the cause of its chemotherapeutic failures. Based on the described problem, new treatment alternatives urgently need to be developed. The aim of the present research was to study the in vitro and in vivo efficacy of cannabidiol (CBD), the second most abundant component of the Cannabis sativa plant, was demonstrated against E. granulosus sensu stricto. CBD (50 µg/mL) caused a decrease in protoscoleces viability of 80 % after 24 h of treatment which was consistent with the observed tegumental alterations. Detachment of the germinal layer was observed in 50 ± 10% of cysts treated with 50 µg/mL of CBD during 24 h. In the clinical efficacy study, all treatments reduced the weight of cysts recovered from mice compared with the control group. However, this reduction was only significant with ABZ suspension and the CBD + ABZ combination. As we could observe by the SEM study, the co-administration of CBD with ABZ suspension caused greater ultrastructural alteration of the germinal layer in comparison with that provoked with the monotherapy. Further in vivo research will be conducted by changing the dose and frequency of CBD and CBD + ABZ treatments and new available CBD delivery systems will also be assayed to improve bioavailability in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%